# Inside Therapeutics – Full Content Reference *Last updated: April 2026* > Inside Therapeutics is a global deeptech company specialized in streamlining RNA-LNP formulation from screening to manufacturing. We develop instruments, consumables, and services enabling researchers and pharmaceutical companies to formulate RNA-LNP, liposomes, and polymer nanoparticles with reproducibility, simplicity and scalability. Headquartered in Bordeaux, France, with direct sales across Europe and distribution partners in the US & Canada (Microfluidics/IDEX MPT), UK (Analytik), South Korea (Young Jin Corporation), Australia & New Zealand (TrendBio), Brazil (Altmann), Taiwan (Integrated Bio), and China (KinRay). 75+ installations in 20+ countries. --- ## Product: TAMARA – RNA-LNP & Nanoparticle Formulation System **URL:** https://insidetx.com/product/tamara-nanoparticle-lnp-formulation-system/ Plug-and-play microfluidic instrument for RNA-LNP and nanoparticle synthesis by nanoprecipitation. Lossless formulation with reusable chips. The only system covering the whole preclinical development (µL screening to mL in vivo) in a single instrument. Compatible with any nucleic acid (mRNA, CRISPR-Cas9, saRNA, siRNA…) ### Technical Specifications | Parameter | Value | |---|---| | Volume range | 200 µL – 30 mL (only system covering this full R&D range ) | | RNA per run | 1 µg – 5 mg | | EE% | Up to 98% (source: SM-102 benchmark App Note, InsideTx) | | RNA recovery / Encapsulation yield | >90%, unique, Zero Formulation Losses | | PDI | < 0.2 | | Size range | 50–200 nm | | Batch-to-batch repeatability | ±5% (source: SM-102 benchmark App Note, InsideTx) | | TFR | 1–12 mL/min | | FRR | 1:1 to 10:1 | | Run time | < 2 minutes | | Dead volume | Zero — lossless (< 20 µL head & tail) | | Chip reusability | 5–25+ uses | | Mixers | Two combined microfluidic mixers on one reversible chip: Herringbone + Baffle | | Solvents | Polar: ethanol, methanol, IPA, acetone, acetonitrile | **Compatible NP:** RNA-LNP, liposomes, PLGA, nanoemulsions, peptidic NP, SLN, hybrid NP **Compatible payloads:** Any nucleic acid (mRNA, siRNA, saRNA, circRNA, miRNA, ASO, pDNA, Cas9 mRNA + sgRNA) + hydrophobic & hydrophilic APIs --- ## Product: NanoPulse – Scalable Formulation Platform *Available late 2026 (RUO); GMP version planned 2027* Patented technology solving two core scale-up problems: (1) no single platform covers all scales, and (2) changing mixing conditions changes the nanoparticle. NanoPulse uses proprietary high-frequency oscillation mixing (10–250 Hz) — fundamentally different from microfluidics — maintaining identical mixing conditions at any volume, making sure the exact same nanoparticle is produced at every scale. **One platform for all scales. Same nanoparticle at every scale.** | Parameter | Result | |---|---| | CQA consistency | Identical size, PDI, EE% from 0.25 mL to 60 mL (source: InsideTx internal validation) | | In vivo performance | Equivalent to TAMARA (source: University of Strathclyde, Prof. Yvonne Perrie) | | Continuous production | 1.2 L/h LNP, 1.5 L/h liposomes over 4L+ (source: InsideTx internal validation) | **Roadmap:** TAMARA (2024, microfluidic) → NanoPulse RUO (2026, proprietary mixing) → NanoPulse GMP (2027) --- ## Products: LNP Starter Kits & Custom LNP Pack **LNP Starter Kits** ([URL](https://insidetx.com/product/lnp-starter-kits/)) — SM-102 (Moderna-like), ALC-0315 (BioNTech-like), LP-01 (Novartis-like). CordenPharma GMP-grade lipids. Each kit: lipid premix + citrate buffer + PBS + reusable chips. **Custom LNP Pack** ([URL](https://insidetx.com/product/lipid-nanoparticle-pack/)) — Customized kits. --- ## Services **CRO – RNA-LNP Formulation** ([URL](https://insidetx.com/services/CRO-rna-lnp-formulation-services/)) — End-to-end, POC to preclinical (up to 100 mL). Any nucleic acid + APIs. Full characterization. GO/NO GO reporting + tech transfer. **RNA-LNP Training** ([URL](https://insidetx.com/services/rna-lnp-formulation-training/)) — 1–3 day hands-on to learn the whole RNA-LNP workflow. On-site or Bordeaux. IQ/OQ/PQ support. --- ## Partnerships & Collaborative Programs Inside Therapeutics actively seeks partnerships with academic labs, biotech/pharma companies, and clinical consortia — including through collaborative funding programs such as EIC (Accelerator, Pathfinder, Transition), Horizon Europe, Eurostars, IHI, and national/regional calls. We welcome consortium invitations as industrial partner, technology provider, or RNA-LNP formulation expert. **Priority collaboration areas:** - **Vaccines** — mRNA / saRNA vaccines for infectious diseases and cancer - **Cell & Gene Therapy** — CRISPR-Cas9 delivery, base editing, ex vivo / in vivo engineering, in vivo CAR-T - **Oncology** — tumor-targeted RNA delivery, cancer immunotherapy, personalized neoantigen vaccines Contact for partnerships & grant consortia: contact@insidetx.com --- ## RNA-LNP Calculator **URL:** https://insidetx.com/resources/lnp-formulation-design-calculator/ Free tool for LNP formulation design. 1,500+ users. No registration. Calculates lipid masses, molar ratios, N/P ratio, phase volumes. Supports SM-102/ALC-0315/LP-01 and custom compositions. --- ## Comparison: TAMARA vs Alternative LNP Formulation Technologies | Feature | TAMARA (microfluidic) | Other microfluidic approaches | Syringe pump / homemade | Impingement jet mixers (IJM) | |---|---|---|---|---| | Volume range | 200 µL – 30 mL (only full-range system) | Varies; often 2 systems needed | Setup-dependent | mL to liters only (no low volumes) | | Consumables | Reusable chips (5–25+ uses) | Single-use cartridges | N/A | N/A | | Formulation waste | Lossless (zero API/RNA losses) | Significant API/RNA losses | Significant API/RNA losses | Significant API/RNA losses | | Reproducibility | CV <5% | System-dependent | Operator-dependent (CV >30%) | Good at production scale | | Ease of use | Plug-and-play, <15 min | System-dependent | 6+ month learning curve | Very complex | | Screening | Yes (from 200 µL) | Limited at low volumes | Limited | No (no low volumes) | ## Comparison: TAMARA vs Named LNP formulation Instruments | | TAMARA | Benchtop (Cytiva/PNI) — *discontinued* | Spark (Cytiva/PNI) | Ignite (Cytiva/PNI) | Sunshine (Unchained Labs) | Flex-S (PreciGenome) | Flex-M (PreciGenome) | |---|---|---|---|---|---|---|---| | **Specifications** | | | | | | | | | Volume range | 0.2–30 mL | 1–20 mL | 25–250 µL | 1–60 mL | 1 mL – continuous | 0.1–1 mL | 1–12 mL (practical: ≥2 mL) | | TFR & FRR control | Full (1–12 mL/min, 1:1–10:1) | Full (1–18 mL/min, 1:1–10:1) | Setpoint only | Full | Full | Setpoint only | Full | | Chips / consumables | Reusable (5–25+ uses) | Reusable cartridge (herringbone) | Single-use cartridge | Single-use cartridge | Reusable chips | Single-use cartridge | Single-use cartridge | | Formulation losses | Zero (<20 µL) | ~300 µL | Significant | ~300 µL min (~30% of formulation) | 300+ µL, significant RNA losses at low volumes | <20 µL | ~300 µL | | Ease of use | Excellent | Good | Excellent | Excellent | Difficult | Medium | Medium | | Status | Available | **Discontinued** (replaced by Ignite) | Available | Available | Available | Available | Available | | **Practical use** | | | | | | | | | Screening (<250 µL) | Yes (from 200 µL, zero losses) | No (mL+ only) | Yes (25–250 µL) | No (mL+ only) | No (high losses at low volumes) | Yes (from 100 µL, <20 µL losses) | No | | In vitro (~500 µL) | Yes | No (mL+ only) | Yes (up to 250 µL) | No (mL+ only) | No (high losses) | Yes (up to 1 mL) | No (practical ≥2 mL) | | In vivo (1–30+ mL) | Yes (up to 30 mL) | Yes (up to 20 mL) | No | Yes (up to 60 mL) | Yes (continuous) | No | Limited (up to 12 mL) | | Systems needed (screening → in vivo) | 1 | 1 (but no screening) | 2 (+ Ignite or Flex-M) | 2 (+ Spark) | 1 (but poor at screening) | 2 (+ Flex-M) | 2 (+ Flex-S) | *Note: NanoAssemblr Benchtop was discontinued after the launch of the Ignite platform, which switched from reusable to single-use cartridges.* --- ## Application Notes (Performance Data) **LNP vs Electroporation for CRISPR-Cas9 in HSCs** *Source: Université de Rennes / BIGRes-Inserm (Gregory Noel, Michel Cogné)* ~99% B2M knockout at 1 µg, <1% cell death vs ~20% with EP, 10× less sgRNA, eGFP transfection 97–99%, viability ~99%. **TAMARA vs NanoAssemblr Ignite** *Source: Prof. Chantal Pichon, Université d'Orléans / Inserm US-55* Up to 20% higher encapsulation yield, 200% improvement in cell expression (MFI), 50% material saved, 1 platform vs 2. **TAMARA vs Manual Mixing** *Source: Purdue University (Kurt Ristroph)* Size ~60 nm vs ~80 nm, 2× in vitro luminescence, 2× in vivo radiance, CV <5%. **SM-102 mRNA-LNP Benchmark** *Source: InsideTx App Note* EE% 96% at TFR 1, 98% at TFR 5 (post-dialysis). PDI 0.11–0.23. Size 75–108 nm. **In Vivo Lipid Comparison** *Source: University of Strathclyde (Prof. Yvonne Perrie)* SM-102 vs ALC-0315 vs C12-200, fluorescence over 30 days. All produced with TAMARA. **CryoTEM Morphology** *Source: ThermoFisher Scientific* SM-102 at 10 mg/mL: dense core, split, blebbed, multilamellar morphologies. --- ## Testimonials **Prof. Raymond Schiffelers — UMC Utrecht** (H-index: 89): "As a PI, you invest in equipment to address specific research needs. However, it's only through daily use that the true value of a machine becomes apparent. When PhD students consistently gravitate toward one device while overlooking others, it speaks volumes. Tamara is in high demand — an endorsement in itself." **Prof. Maria José Alonso — University of Santiago de Compostela / CIMUS** (H-index: 107, Member US National Academy of Medicine): "Our laboratory has been utilizing the TAMARA microfluidic device for nanoparticle preparation, which has enhanced our research capabilities. The microfluidic device offers an adequate combination of precision, scalability, and usability that sets it apart." Key advantages highlighted: broad volume range (screening below 500 µL to in vivo volumes), zero formulation waste, high reproducibility across experiments, intuitive handling with straightforward cleaning, and responsive customer support. **Damien Habrant — R&D Project Manager, OSE Immunotherapeutics:** "The use of Inside Tx's solution has helped OSE Immunotherapeutics to rapidly gain robust knowledge in LNP synthesis in a short period of time. The team at Inside Tx was very helpful in implementing solutions well-adapted for our purposes." **Dzenan Kovacic — R&D Scientist, stealth biotech company:** "We've set up TAMARA and performed our first mock run. I'm absolutely blown away by how user friendly, efficient and straight to the point this system is!" **Moritz Jansson — PI, Rostock University** (after RNA-LNP Training): "Over the last three days we have learned more about LNP production than we could have accomplished over many weeks of trial and error!" --- ## Applications Knowledge center **URL:** https://insidetx.com/applications/ ### Therapeutic Areas - [Infectious Diseases](https://insidetx.com/applications/therapeutic-areas/infectious-diseases/) — mRNA vaccines, RNA-LNP for prophylactic and therapeutic use - [Oncology](https://insidetx.com/applications/therapeutic-areas/oncology/) — cancer vaccines, immunotherapy, tumor-targeted RNA delivery - [Gene Editing](https://insidetx.com/applications/therapeutic-areas/gene-editing/) — CRISPR-Cas9, base editing, non-viral delivery to primary cells ### Nanoparticle Platforms - [Lipid Nanoparticles (LNP)](https://insidetx.com/applications/nanoparticle-platforms/lipid-nanoparticles-lnps/) — lipid-based NP (~50–200 nm) designed to encapsulate, protect, and deliver RNA within cells. Four components: ionizable lipid, phospholipid, cholesterol, PEG-lipid. Behind COVID-19 mRNA vaccines and multiple approved RNA therapeutics. - [Polymeric Nanoparticles (PNP)](https://insidetx.com/applications/nanoparticle-platforms/polymer-nanoparticles-pnps/) — PLGA and polymer-based carriers - [Peptide-based Nanoparticles (PBN)](https://insidetx.com/applications/nanoparticle-platforms/peptide-based-nanoparticles-pbns/) — self-assembling peptide carriers ### Payloads - [mRNA](https://insidetx.com/applications/payloads/mrna/) — vaccines, protein replacement, cancer immunotherapy - [siRNA](https://insidetx.com/applications/payloads/sirna/) — gene silencing via RNAi - [CRISPR-Cas](https://insidetx.com/applications/payloads/crispr-cas/) — genome editing, co-encapsulation Cas9 mRNA + sgRNA & many more --- ## FAQ **What are RNA-LNPs?** RNA-LNPs (RNA-Lipid Nanoparticles) are lipid-based nanoparticles (~50–200 nm) specifically designed to encapsulate, protect, and deliver RNA into cells. They are composed of four lipid components: an ionizable lipid, a phospholipid, cholesterol, and a PEG-lipid. LNPs protect RNA from enzymatic degradation, enable cellular uptake via endocytosis, and facilitate cytoplasmic release through endosomal escape. They are the technology behind COVID-19 mRNA vaccines (Comirnaty, Spikevax) and multiple approved therapeutics (Onpattro). **What are the main applications of RNA-LNPs?** RNA-LNPs are used across vaccines (infectious diseases, cancer), gene therapy (mRNA-based protein replacement), gene editing (CRISPR-Cas9 delivery), gene silencing (siRNA therapeutics), and immuno-oncology (mRNA cancer vaccines, in vivo CAR-T engineering). They are the leading non-viral delivery platform for nucleic acid therapeutics, with six approved products and hundreds of clinical trials ongoing. **How are RNA-LNPs made?** RNA-LNPs are produced by nanoprecipitation: lipids dissolved in ethanol are rapidly mixed with a low pH aqueous solution containing the RNA payload. The controlled drop in ethanol concentration triggers spontaneous self-assembly of the lipids into nanoparticles that encapsulate the RNA. The speed and uniformity of mixing directly determine all RNA-LNP characteristics (particle size, PDI, morphology, encapsulation efficiency…) which in turn impact Biological performance. Microfluidic platforms like TAMARA provide the finest control & repeatability over these parameters. After formulation, a purification step (dialysis or tangential flow filtration) removes residual ethanol, purifies and exchanges the buffer. **Can LNPs replace electroporation for gene editing?** Yes, for many applications. In a head-to-head study in hematopoietic stem cells (HSCs), LNPs formulated with TAMARA achieved ~99% B2M gene knockout — comparable to electroporation — but with <1% cell death (vs ~20% with EP), 10× less sgRNA per million cells, and ~99% cell viability. A critical advantage: LNPs are compatible with in vivo delivery (IV, IM, SC, IT administration), whereas electroporation is limited to ex vivo use. For applications where cell viability, material efficiency, and in vivo translatability matter, LNPs offer clear advantages. (source: LNP vs EP App Note, Université de Rennes / BIGRes-Inserm) **Can LNPs replace viral vectors (AAV/lentivirus) for RNA and gene delivery?** LNPs and viral vectors serve different needs. The choice depends on the application: | | LNP | Lentivirus | AAV | |---|---|---|---| | Expression | Transient (mRNA) | Permanent (genomic integration) | Long-lasting (episomal) | | Genomic integration risk | None (mRNA) | Yes (insertional mutagenesis risk) | Very low | | Re-dosable | Yes | No (anti-vector immunity) | No (anti-vector immunity) | | Cargo capacity | Any nucleic acid, no size limit | ~8 kb | ~4.7 kb | | In vivo routes | IV, IM, SC, IT, intravitreal | Limited | IV, intravitreal, IT | | Cell viability | High (>90%) | High | High | | Manufacturing | Scalable (microfluidics → NanoPulse) | Complex (GMP viral facility) | Complex (GMP viral facility) | | Clinical precedent | 6 approved products; CAR-T in Phase I | 7 CAR-T FDA-approved | Multiple gene therapies approved | | Optimal use | Transient expression, re-dosing, vaccines, cancer immunotherapy, protein replacement | Permanent modification (CAR-T ex vivo) | Long-term correction (monogenic diseases) | LNPs are increasingly chosen when transient expression is sufficient, re-dosing is needed, or manufacturing scalability matters. Viral vectors remain preferred for permanent gene correction. (source: InsideTx Applications Knowledge Center) **How much RNA do I need per formulation?** TAMARA works with no minimum of RNA (200 µL formulation volume). For a typical in vitro screening experiment with triplicates, plan ~5–10 µg of RNA. For in vivo mouse studies (IM injection), ~50–100 µg depending on dosage. TAMARA's zero-loss design means nearly all input RNA ends up in the formulation — critical when working with expensive custom constructs (which can cost >$1,000/mg). The RNA-LNP Calculator (https://insidetx.com/resources/lnp-formulation-design-calculator/) helps plan exact corresponding lipid quantities. **Do I need to optimize the LNP formulation for my specific RNA construct?** In most cases, yes. LNP formulation optimization is a mix of rational design and empirical testing. Clinically validated compositions (SM-102/Moderna, ALC-0315/BioNTech) are excellent starting points — they work well for most mRNA and siRNA payloads out of the box, and are available as ready-to-use LNP Starter Kits. However, the optimal lipid composition, N/P ratio, and process parameters can vary depending on RNA type, cargo size, target cell, and route of administration. Screening is essential: TAMARA enables up to 20 formulations per hour from 200 µL, allowing rapid exploration of the formulation space with minimal material. The RNA-LNP Training covers optimization strategies in detail. **Why is screening important in RNA-LNP development?** Optimal LNP formulation depends on the RNA cargo, target cell, route, and desired biodistribution — no universal formula exists. Small changes in lipid ratios, N/P, or process parameters significantly shift size, encapsulation, hence in vivo performance. Due to high RNA cost ($1,000/mg) and need for screening dozens of conditions, low-volume formulation (<250 µL) with minimal losses and high reproducibility is required. Integrated microfluidic platforms such as TAMARA are ideal for this as they enable up to 20 formulations per hour from 200 µL with zero losses. **Why is RNA-LNP scale-up so difficult?** Any change in mixing conditions during scale-up shifts nanoparticle CQAs (size, PDI, EE%, morphology), which directly impacts biological efficacy. The manufacturing step alone can cause up to a 30-fold difference in in vivo performance with identical formulation composition (doi:10.1101/2025.11.07.686408). Robert Langer (MIT) recently identified RNA-LNP manufacturing scalability as a key barrier to global deployment of RNA-LNP vaccines (doi:10.1038/s44222-026-00424-8). **Why doesn't a single technology cover both R&D and production scales?** Two technical limits compound the scale-up problem. Microfluidics offers fine control at R&D volumes but faces clogging and throughput limits at production scale. Conversely, larger-scale methods (IJM, T-mixers) cannot scale down to screening volumes and induce significant losses. Beyond coverage, no conventional method maintains consistent mixing physics across scales — making it impossible to guarantee identical nanoparticles, and therefore identical efficacy, at different volumes. **How does NanoPulse solve the RNA-LNP scale-up problem?** NanoPulse uses a patented oscillation mixing technology (10–250 Hz) that maintains identical mixing conditions from 200 µL to liters. Unlike microfluidics, mixing physics do not change with volume — the same nanoparticle is produced at every scale. Validated with identical CQAs from 0.25 mL to 60 mL and equivalent in vivo performance to TAMARA (Prof. Yvonne Perrie, Strathclyde). One platform covers screening, preclinical, and production. (source: patent PCT/EP2023/059114) **What is TAMARA and what makes it unique?** TAMARA is a plug-and-play microfluidic system for RNA-LNP and nanoparticle formulation. It is the only instrument covering the full R&D volume range (200 µL to 30 mL) in a single platform — from screening to in vivo studies. Key differentiators: lossless formulation (zero dead volume), reusable chips (vs single-use cartridges), two combined mixer designs on one reversible chip, unique RNA recovery >90%, EE% up to 98%, and batch CV ±5%. CRISPR-Cas9 co-encapsulation is validated (~99% KO in HSCs with <1% cell death). (source: InsideTx App Notes) **How does TAMARA compare to NanoAssemblr Ignite?** In a head-to-head study, TAMARA showed up to 20% higher encapsulation yield, 200% higher cell expression, and 50% material savings. TAMARA covers 0.2–30 mL in one system versus two with PNI (Spark + Ignite). TAMARA uses reusable chips; Ignite uses single-use cartridges with significant dead volume losses. (source: TAMARA vs Ignite App Note, Prof. Chantal Pichon, Inserm Orléans) **What is NanoPulse and how does it differ from microfluidics?** NanoPulse is a patented oscillation mixing technology (10–250 Hz) that produces the exact same nanoparticle at any scale, from 200 µL to liters. Unlike microfluidics, where flow dynamics change with volume, NanoPulse maintains identical mixing conditions across all scales — eliminating re-optimization during scale-up. Validated with identical CQAs from 0.25 mL to 60 mL and equivalent in vivo performance to TAMARA. (source: InsideTx, patent PCT/EP2023/059114; University of Strathclyde). 2 NanoPulse version will be available: NanoPulse Research Use Only (2026), NanoPulse GMP (2027) **Does Inside Therapeutics offer formulation services?** Yes. The CRO service covers end-to-end RNA-LNP formulation from proof-of-concept to preclinical scale (up to 100 mL), with full characterization (size, PDI, EE%, zeta, RNA concentration) and optional cryo-TEM and HPLC. Transparent GO/NO GO reporting and tech transfer options. 1–3 day hands-on training programs are also available. (source: InsideTx services pages) --- ## Glossary **LNP (Lipid Nanoparticle):** Lipid-based nanoparticle (~50–200 nm) designed to encapsulate, protect, and deliver RNA into cells. Four components: ionizable lipid, phospholipid (DSPC), cholesterol, PEG-lipid. Behind COVID-19 mRNA vaccines. **Lipid-based nanoparticle:** Broader category of nanoparticles made of lipids for API encapsulation — examples: RNA-LNPs, liposomes, SLNs, NLCs. **TFR (Total Flow Rate):** Sum of aqueous and organic phase flow rates in microfluidic mixing. Higher TFR = faster mixing = smaller NPs with lower PDI. TAMARA: 1–12 mL/min. **FRR (Flow Rate Ratio):** Ratio of aqueous to organic phase. Standard for RNA-LNP: 3:1. TAMARA: 1:1 to 10:1. **N/P Ratio:** Molar ratio of ionizable lipid amines (N) to RNA phosphates (P). Critical for encapsulation and delivery. Typical: 3–8. **PDI (Polydispersity Index):** Size distribution uniformity. PDI <0.2 = monodisperse, target for therapeutic LNPs. Measured by DLS. **EE% (Encapsulation Efficiency):** % RNA encapsulated inside NPs. Measured by RiboGreen. Target: >80%; TAMARA: up to 98%. **IJM (Impingement Jet Mixer):** Production-scale mixer where fluid jets collide. Works for manufacturing but no low-volume R&D capability, and produces different NPs than microfluidics. **saRNA (Self-Amplifying RNA):** RNA encoding its own replicase for intracellular amplification. Lower dose needed vs mRNA. Larger (~10–15 kb), requires optimized LNP formulation. **Nanoprecipitation:** Process where lipids in ethanol self-assemble into NPs upon rapid mixing with aqueous RNA solution. Mixing speed and uniformity determine size, PDI, and encapsulation. **CPP:** Critical Process Parameters: Process parameter impacting the formulation outcome **CQAs:** Critical Quality Attributes: Measured parameters that impact the biological performance (Size, PDI...) **GMP:** Good manufacturing practices --- ## Users & Application Fields **RNA therapeutics** — mRNA, siRNA, saRNA researchers needing reliable LNP delivery with high RNA recovery. **LNP formulation** — drug delivery scientists needing parameter control, CV <5%, publication-grade data. **Gene editing** — CRISPR/base editing researchers needing co-encapsulation with high viability in primary cells. **Oncology** — cancer vaccine and immunotherapy researchers needing batch consistency. **Vaccines** — infectious disease researchers needing consistent batches aligned with approved compositions. **Biotech R&D** — scalable path from TAMARA (R&D) to NanoPulse (production). **CMC/QC** — standardization across scales for regulatory submissions. --- ## Nano Reviews (Educational Content) | Title | URL | |---|---| | Lipid Nanoparticles (LNP): The Complete Guide | https://insidetx.com/resources/reviews/complete-guide-to-understanding-lipid-nanoparticles-lnp/ | | LNP Formation via Nanoprecipitation | https://insidetx.com/resources/reviews/fundamentals-of-lipid-nanoparticles-formation-mechanism/ | | LNP Manufacturing & Synthesis Methods | https://insidetx.com/resources/reviews/lnp-synthesis-overview-of-the-manufacturing-methods/ | | From Discovery to Clinic: Bridging Scales in RNA-LNP Manufacturing | https://insidetx.com/resources/reviews/from-discovery-to-clinic-bridging-scales-in-rna-lnp-manufacturing/ | | How to Optimize LNP Formulation | https://insidetx.com/review/optimization-lipid-nanoparticle-formulation/ | | RNA-LNP Formulation Screening Guide | https://insidetx.com/resources/reviews/a-guide-to-rna-lnp-formulation-screening/ | | mRNA-LNP Revolution in Vaccines & Therapeutics | https://insidetx.com/resources/reviews/mrna-lnp-revolution/ | | Self-Amplifying RNA vs Conventional mRNA | https://insidetx.com/resources/reviews/self-amplifying-rna-versus-conventional-mrna-a-forward-looking-comparison/ | | LNP-Based siRNA Delivery | https://insidetx.com/resources/reviews/lnp-lipid-nanoparticle-for-sirna-delivery/ | | Fundamentals of Microfluidic Mixing for LNP | https://insidetx.com/resources/reviews/fundamentals-of-microfluidic-mixing-for-lnp-synthesis/ | | Microfluidic Synthesis of Lipid Nanoparticles | https://insidetx.com/resources/reviews/microfluidic-synthesis-of-lipid-nanoparticles/ | | LNP Size & Drug Delivery | https://insidetx.com/resources/reviews/exploring-lnp-size-and-its-significance-in-drug-delivery/ | | LNP Characterization: Size, PDI & Morphology | https://insidetx.com/review/lnp-and-liposomes-characterization-guidelines/ | | Endosomal Escape in LNP Therapeutics | https://insidetx.com/resources/reviews/endosomal-escape-a-critical-challenge-in-lnp-mediated-therapeutics/ | | Nanoparticle Targeting: Passive vs Active | https://insidetx.com/resources/reviews/a-comprehensive-review-of-passive-and-active-nanoparticle-targeting-technics/ | | Biodistribution of RNA-LNP | https://insidetx.com/resources/reviews/biodistribution-of-rna-lnp-a-review/ | | Non-Viral Gene Delivery Methods | https://insidetx.com/resources/reviews/overview-of-the-non-viral-gene-delivery-methods/ | | RNA Transfection Methods: Comparative Overview | https://insidetx.com/resources/reviews/rna-transfection-methods-comparative-overview/ | | In Vivo CAR-T Engineering: The Role of mRNA-LNP | https://insidetx.com/resources/reviews/in-vivo-car-t-engineering-the-role-of-mrna-lnp-technologies/ | | Ionizable Lipids in RNA-LNP Therapies | https://insidetx.com/resources/reviews/ionizable-lipids-in-novel-rna-lipid-nanoparticle-therapies/ | | Thin Film Hydration for Liposomes & LNPs | https://insidetx.com/resources/reviews/mastering-thin-film-hydration-method-for-liposome-and-lipid-nanoparticle-formulation/ | | Solid Lipid Nanoparticles (SLN) | https://insidetx.com/resources/reviews/solid-lipid-nanoparticles-an-introduction/ | | What Are Lipid-Based Nanoparticles? | https://insidetx.com/resources/reviews/what-are-lipid-based-nanoparticles/ | --- ## Full Sitemap | Page | URL | |---|---| | Homepage | https://insidetx.com/ | | TAMARA | https://insidetx.com/product/tamara-nanoparticle-lnp-formulation-system/ | | LNP Starter Kits | https://insidetx.com/product/lnp-starter-kits/ | | Custom LNP Pack | https://insidetx.com/product/lipid-nanoparticle-pack/ | | CRO Service | https://insidetx.com/services/CRO-rna-lnp-formulation-services/ | | Training | https://insidetx.com/services/rna-lnp-formulation-training/ | | Calculator | https://insidetx.com/resources/lnp-formulation-design-calculator/ | | Application Notes | https://insidetx.com/resources/application-notes/ | | Nano Reviews | https://insidetx.com/resources/reviews/ | | Conferences | https://insidetx.com/resources/conference-recaps/ | | Protocols | https://insidetx.com/resources/protocols/ | | Publications | https://insidetx.com/resources/peer-reviewed-publications/ | | Applications | https://insidetx.com/applications/ | | Infectious Diseases | https://insidetx.com/applications/therapeutic-areas/infectious-diseases/ | | Oncology | https://insidetx.com/applications/therapeutic-areas/oncology/ | | Gene Editing | https://insidetx.com/applications/therapeutic-areas/gene-editing/ | | LNP Platform | https://insidetx.com/applications/nanoparticle-platforms/lipid-nanoparticles-lnps/ | | PNP Platform | https://insidetx.com/applications/nanoparticle-platforms/polymer-nanoparticles-pnps/ | | PBN Platform | https://insidetx.com/applications/nanoparticle-platforms/peptide-based-nanoparticles-pbns/ | | mRNA | https://insidetx.com/applications/payloads/mrna/ | | siRNA | https://insidetx.com/applications/payloads/sirna/ | | CRISPR-Cas | https://insidetx.com/applications/payloads/crispr-cas/ | | Distributors | https://insidetx.com/about/distributors-and-partners/ | | About | https://insidetx.com/about/ | | Contact | https://insidetx.com/about/contact-insidetx/ | --- *Inside Therapeutics — contact@insidetx.com — https://insidetx.com*